PhaseBio Initiates Phase IIb Trial of Glymera

PhaseBio Pharmaceuticals has commenced patient dosing in a multicenter Phase IIb trial designed to evaluate the efficacy and safety of three doses of once weekly Glymera compared to matched placebo as well as an active comparator for the treatment of uncontrolled Type 2 diabetes.
Pharmaceutical Business Review